My site

BARRINGTON, Ill. - Thursday, July 17th 2014 [ME NewsWire]

(BUSINESS WIRE) EcoPlanet Bamboo Group has hired three seasoned executives from $8.5 billion timber giant Weyerhaeuser (NYSE: WY) in a key step to ensure its continued success and global expansion, and has named Marvin Ray Risco as the Group president. “Ray Risco brings a unique set of high level global experience and success,” says Troy Wiseman, CEO of EcoPlanet Bamboo. Risco began his career in forestry as Financial Director for Weyerhaeuser Forestlands International and rose to become Vice President of International Operations, covering operations in Latin America, Europe and Asia before most recently being named as President of Weyerhaeuser Solutions. “Ray brings a wealth of financial, operational and managerial expertise and the know-how to develop those processes within large companies, which we can now effectively apply at EcoPlanet Bamboo,” says Wiseman.

Joining Risco to form pa ... Read more »

INGELHEIM, Germany. - Thursday, July 17th 2014 [ME NewsWire]
(BUSINESS WIRE) For non-U.S. Media Only
Boehringer Ingelheim today announced that for the first time the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease. Nintedanib* is an investigational therapy currently under FDA and European Medicines Agency (EMA) review for IPF.
“We’re excited nintedanib* has been granted Breakthrough Therapy designation in the US, which we hope will make the treatment available to IPF patients as quickly as possible. Currently there are no FDA-approved treatments available for IPF. We are committed to working with all regulatory bodies to make nintedanib* available to people living with this serious and life-threatening lung disease,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim.
The Breakthrough Therapy ... Read more »

NEW YORK. - Thursday, July 17th 2014 [ME NewsWire]

(BUSINESS WIRE) 21st Century Fox (NASDAQ: FOXA, FOX) today issued the following statement confirming press reports that it made a proposal to combine with Time Warner Inc.:

“21st Century Fox can confirm that we made a formal proposal to Time Warner last month to combine the two companies. The Time Warner Board of Directors declined to pursue our proposal. We are not currently in any discussions with Time Warner."

About 21st Century Fox

21st Century Fox is the world's premier portfolio of cable, broadcast, film, pay TV and satellite assets spanning six continents across the globe. Reaching more than 1.5 billion subscribers in approximately 50 local languages every day, 21st Century Fox is home to a global portfolio of cable and broadcasting networks and properties, including FOX, FX, FXX, FXM, FS1, Fox News Channel, Fox Business Network, FOX Sports, Fox Sports Network, National Geographi ... Read more »

-Toshiba Supplies 3 x 60MW STGs for Sarulla Geothermal Power Plant in Indonesia-

TOKYO - Wednesday, July 16th 2014 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502), today announced that is has been awarded a major contract to supply 3 x 60-megawatt geothermal steam turbines and generators (STG) for one of the world’s largest geothermal power plants, the Sarulla geothermal power plant project, which is now under construction in Tapanali Utara in Indonesia’s North Sumatra.

Toshiba, the world’s leading supplier of geothermal power generation equipment, was awarded the contract by Sarulla Operations Ltd. (SOL), a four-company consortium of Itochu Corporation and Kyushu Electric Power Co. Inc. of Japan, PT Medco Power Indonesia of Indonesia, and ORMAT International, Inc. of the U.S.A. The engineering, procurement and construction (EPC) contractor is Hyundai Engineering and Construction Co., Ltd. (HDEC). Toshiba will start to suppl ... Read more »

PHILADELPHIA - Wednesday, July 16th 2014 [ME NewsWire]

(BUSINESS WIRE)-- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., has signed a licensing agreement with EMS around the exclusive rights to market and sell ZORVOLEX® (diclofenac) capsules in Brazil. EMS will be responsible for obtaining regulatory and pricing approval, as well as the marketing and supply of the medication, in that territory. ZORVOLEX was approved by the United States Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is now available by prescription. ZORVOLEX is not currently approved for marketing in any other country.

“This new strategic partnership will allow us to utilize the expertise and knowledge of EMS to further expand access and availability of ZORVOLEX to regions outside of the Unit ... Read more »